Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Depreciation and Depletion (2020 - 2022)

Historic Depreciation and Depletion for Protagonist Therapeutics (PTGX) over the last 3 years, with Q4 2022 value amounting to $254000.0.

  • Protagonist Therapeutics' Depreciation and Depletion rose 808.51% to $254000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $1.0 million, marking a year-over-year increase of 2693.73%. This contributed to the annual value of $894000.0 for FY2024, which is 849.54% down from last year.
  • Per Protagonist Therapeutics' latest filing, its Depreciation and Depletion stood at $254000.0 for Q4 2022, which was up 808.51% from $270000.0 recorded in Q3 2022.
  • Protagonist Therapeutics' 5-year Depreciation and Depletion high stood at $270000.0 for Q3 2022, and its period low was $180000.0 during Q1 2021.
  • Over the past 3 years, Protagonist Therapeutics' median Depreciation and Depletion value was $235000.0 (recorded in 2021), while the average stood at $225888.9.
  • Examining YoY changes over the last 5 years, Protagonist Therapeutics' Depreciation and Depletion showed a top increase of 4000.0% in 2022 and a maximum decrease of 808.51% in 2022.
  • Over the past 3 years, Protagonist Therapeutics' Depreciation and Depletion (Quarter) stood at $188000.0 in 2020, then increased by 25.0% to $235000.0 in 2021, then increased by 8.09% to $254000.0 in 2022.
  • Its Depreciation and Depletion was $254000.0 in Q4 2022, compared to $270000.0 in Q3 2022 and $259000.0 in Q2 2022.